Vivos Therapeutics (VVOS) Other Operating Expenses (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Other Operating Expenses data on file, last reported at -$7.8 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at -$7.8 million, down 73.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$18.9 million (down 48.35% YoY), and the FY2025 annual result was -$21.2 million, down 77.65% from the prior year.
• Other Operating Expenses declined to -$7.8 million in Q1 2026 per VVOS's latest filing, from -$5.8 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $1.7 million in Q2 2022 and troughed at -$7.8 million in Q1 2026.
• A 5-year average of -$1.4 million and a median of $555000.0 in 2023 frame the typical range for Other Operating Expenses.
• On a YoY basis, Other Operating Expenses climbed as much as 104.97% in 2025 and fell as far as 737.52% in 2025.
• A 5-year view of Other Operating Expenses shows it stood at $1.2 million in 2022, then slumped by 54.66% to $555000.0 in 2023, then slumped by 708.65% to -$3.4 million in 2024, then tumbled by 71.11% to -$5.8 million in 2025, then sank by 34.1% to -$7.8 million in 2026.
• Business Quant data shows VVOS's Other Operating Expenses at -$7.8 million in Q1 2026, -$5.8 million in Q4 2025, and -$5.5 million in Q3 2025.